Correction: Chen et al. Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma. Biomedicines 2022, 10, 130
by
,
Kai Chen
1,†, 
Yingnan Si
1,†,
Jia-Shiung Guan
2,
Zhuoxin Zhou
1,
Seulhee Kim
2,
Taehyun Kim
2,
Liang Shan
3,
Christopher D. Willey
4,
Lufang Zhou
2,* and
Xiaoguang Liu
1,* 1
Department of Biomedical Engineering, University of Alabama at Birmingham (UAB), 1825 University Blvd, Birmingham, AL 35294, USA
2
Department of Medicine, University of Alabama at Birmingham (UAB), 703 19th Street South, Birmingham, AL 35294, USA
3
School of Nursing, University of Alabama at Birmingham (UAB), 1701 University Blvd, Birmingham, AL 35294, USA
4
Department of Radiation Oncology, University of Alabama at Birmingham (UAB), 1700 6th Avenue South, Birmingham, AL 35294, USA
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Biomedicines 2024, 12(1), 86; https://doi.org/10.3390/biomedicines12010086
Submission received: 15 August 2023
/
Accepted: 3 November 2023
/
Published: 29 December 2023
(This article belongs to the Special Issue Small Extracellular Vesicles: A Novel Avenue for Brain Tumor Management)
Error in Figure
In the original publication [1], there was a mistake in Figure 6. In vivo evaluation of the anti-GBM efficacy of mAb-EV-Ver-A as published. The incorrect baseline IVIS image was used. The corrected Figure 6. In vivo evaluation of the anti-GBM efficacy of mAb-EV-Ver-A appears below. The original publication has been updated to reflect the author’s current institutional email address. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Chen, K.; Si, Y.; Guan, J.-S.; Zhou, Z.; Kim, S.; Kim, T.; Shan, L.; Willey, C.D.; Zhou, L.; Liu, X. Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma. Biomedicines 2022, 10, 130. [Google Scholar] [CrossRef] [PubMed]
Figure 6.
In vivo evaluation of the anti-GBM efficacy of mAb-EV-Ver-A. All mice were treated with 1 mg/kg TMZ daily on days 7–12. (A) Representative IVIS images of GBM intracranial xenograft mice treated with EGFR mAb-EV-Ver-A on days 12, 16, 23, 30, and 34. (B) Tumor flux, volume fold change, and body weight profiles. Tumor growth was monitored by measuring the FLuc bioluminescence using IVIS, and body weight was measured every 3–4 days. The blue arrows indicate the I.P. administration of TMZ. The red arrows indicate the I.V. administration of mAb-EV-Ver-A. ○: PBS (control); ●: 1.0 mg/kg mAb-EV-Ver-A; ■: 3.0 mg/kg mAb-EV-Ver-A; and ▲: 3.0 mg/kg mAb-EV-Ver-A in combination with VEGF mAb injection on Q3/7Dx7. ** p < 0.005 vs. control using ANOVA followed by Dunnett’s t-test. Data represent mean ± SEM, n = 5. (C) Representative H&E staining of brain tissue section. Scale bar: 1 mm.
Figure 6.
In vivo evaluation of the anti-GBM efficacy of mAb-EV-Ver-A. All mice were treated with 1 mg/kg TMZ daily on days 7–12. (A) Representative IVIS images of GBM intracranial xenograft mice treated with EGFR mAb-EV-Ver-A on days 12, 16, 23, 30, and 34. (B) Tumor flux, volume fold change, and body weight profiles. Tumor growth was monitored by measuring the FLuc bioluminescence using IVIS, and body weight was measured every 3–4 days. The blue arrows indicate the I.P. administration of TMZ. The red arrows indicate the I.V. administration of mAb-EV-Ver-A. ○: PBS (control); ●: 1.0 mg/kg mAb-EV-Ver-A; ■: 3.0 mg/kg mAb-EV-Ver-A; and ▲: 3.0 mg/kg mAb-EV-Ver-A in combination with VEGF mAb injection on Q3/7Dx7. ** p < 0.005 vs. control using ANOVA followed by Dunnett’s t-test. Data represent mean ± SEM, n = 5. (C) Representative H&E staining of brain tissue section. Scale bar: 1 mm.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Chen, K.; Si, Y.; Guan, J.-S.; Zhou, Z.; Kim, S.; Kim, T.; Shan, L.; Willey, C.D.; Zhou, L.; Liu, X. Correction: Chen et al. Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma. Biomedicines 2022, 10, 130. Biomedicines 2024, 12, 86. https://doi.org/10.3390/biomedicines12010086
AMA Style
Chen K, Si Y, Guan J-S, Zhou Z, Kim S, Kim T, Shan L, Willey CD, Zhou L, Liu X. Correction: Chen et al. Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma. Biomedicines 2022, 10, 130. Biomedicines. 2024; 12(1):86. https://doi.org/10.3390/biomedicines12010086
Chicago/Turabian StyleChen, Kai, Yingnan Si, Jia-Shiung Guan, Zhuoxin Zhou, Seulhee Kim, Taehyun Kim, Liang Shan, Christopher D. Willey, Lufang Zhou, and Xiaoguang Liu. 2024. "Correction: Chen et al. Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma. Biomedicines 2022, 10, 130" Biomedicines 12, no. 1: 86. https://doi.org/10.3390/biomedicines12010086
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
